They meet with FDA Feb/March 2019. Very confident they can satisfy the regulator.
The new Penthrox inhaler is planned for 2020.
Third interview of new product development manager scheduled.
Overseas interest in CSIRO technology and large molecule product (even incredulity in some quarters that the tech works), but still early days.
May see more interest from big Pharma in buyout when USA approves Penthrox. Pure speculation at present.
Board radiates strong confidence.
We must be patient.
AGM, page-13
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.78M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 40.0¢ | $2.38K | 5.949K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 49806 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 5993 | 2 |
View Market Depth
| Last trade - 10.04am 09/08/2024 (20 minute delay) ? |
| MVP (ASX) Chart |